DIRS.INFO The most relevant business & tech news

☆ Cigna-Humana Merger Is Likely to Face Antitrust Challenge
▼ + stars: | 2023-11-30 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/business/cigna-humana-merger-is-likely-to-face-antitrust-challenge-498636bc

Persons: Dow Jones

☆ Can a Big Pharma Ever Be Worth $1 Trillion?
▼ + stars: | 2023-11-29 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Daniel Skovronsky, chief scientific and medical officer at Eli Lilly, pushed the company to move more quickly and focus more on science. Photo: Maddie McGarvey for The Wall Street JournalThere are five tech companies valued at over $1 trillion. In healthcare, the closest contender is Eli Lilly . This year it became the first big pharmaceutical to surpass a market capitalization of $500 billion thanks to the popularity of its obesity and diabetes medications and, to a lesser extent, its experimental Alzheimer’s drug. But hanging over Lilly and rival Novo Nordisk is a reality that puts the brakes on big pharma’s ascent: the patent cliff.

Persons: Daniel Skovronsky, Eli Lilly, Maddie McGarvey, Lilly Organizations: Wall, Novo Nordisk

Charley GrantCharley Grant is a banking reporter at The Wall Street Journal based in New York. Previously, he was a Heard on the Street columnist. He is a CFA charter holder.

Persons: Charley Grant Charley Grant Organizations: Wall, Journal, CFA Locations: New York

☆ Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding
▼ + stars: | 2023-11-17 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Makers of medical devices were prepared for doom and gloom following a study of obesity drugs and cardiovascular health—but the bearish scenario hasn’t panned out. Photo: Catherine Ivill/Getty ImagesThere is a bit of cognitive dissonance in healthcare investing right now. After reviewing the highly anticipated results from a study of Novo Nordisk’s blockbuster obesity treatment Wegovy released over the weekend, cardiologists at a major medical meeting and the pharma crowd on Wall Street were broadly upbeat. “Today’s confirmatory results lay the groundwork for the coming paradigm shift of metabolic treatment,” gushed Evan Seigerman, an analyst at BMO Capital Markets.

Persons: Catherine Ivill, Novo, Wegovy, ” gushed Evan Seigerman Organizations: pharma, BMO Capital Markets

☆ Obesity Drug Demand Outstrips Supply
▼ + stars: | 2023-11-02 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Diabetes drugs could become an effective way to treat behavioral issues and addiction. WSJ’s Daniela Hernandez breaks down the science on how they work and how they could change psychiatry forever. Photo illustration: Elizabeth SmelovEli Lilly ’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to a surge in demand. Whether there will be enough of the drug is a different question. Both Lilly and its competitor, Denmark’s Novo Nordisk , which makes Ozempic and its sister drug Wegovy, are struggling to meet skyrocketing demand for their medications.

Persons: WSJ’s Daniela Hernandez, Elizabeth Smelov Eli Lilly ’, Mounjaro, Lilly Organizations: Drug Administration, Denmark’s, Denmark’s Novo Nordisk Locations: Denmark’s Novo

☆ The ‘Ozempic Effect’ on Wall Street Has Gone Overboard
▼ + stars: | 2023-11-01 | by ( Charley Grant | David Wainer | ) www.wsj.com time to read: 1 min

America leads developed nations when it comes to obesity. Those paying close attention to the stock market and recent corporate earnings calls might be forgiven for thinking the problem has been solved. Call it the Ozempic effect. A new generation of highly effective weight-loss and diabetes drugs known as GLP-1s has led to fanciful assumptions on Wall Street that spell doom for companies that have profited from America’s obesity problem. It has also led to speculation that gigantic opportunities await those that would benefit from the aggregate weight loss.

☆ Never Mind Covid, Investors Want a Pfizer Obesity Pill
▼ + stars: | 2023-10-31 | by ( David Wainer | ) www.wsj.com time to read: +1 min

Pfizer says it hasn’t gotten the data on its experimental oral obesity medication. It is little wonder, then, that investors were hoping Pfizer could jump to the winning camp with an obesity pill. But the company’s silence on its experimental oral medication, danuglipron, during its earnings release Tuesday, is worrying Wall Street. “Not one mention [of danuglipron] in the prepared remarks from Pfizer,” noted Will Sevush , a healthcare strategist for Jefferies. Before today’s earnings, David Risinger , a Leerink Partners analyst, had written that Pfizer might even release data from its midstage study alongside the earnings results as soon as Tuesday.

Persons: hasn’t, Gabby Jones, Eli Lilly, ”, Will Sevush, Jefferies, David Risinger, Albert Bourla, TD Cowen, Steva Scala Organizations: Pfizer, The Wall, Novo Nordisk, Moderna, Partners

☆ ‘Guided Missile Drugs’ Could Be Big Pharma’s Secret Weapon
▼ + stars: | 2023-10-26 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Merck and Daiichi Sankyo agreed to jointly develop and commercialize three potential antibody-drug conjugates in a deal worth up to $22 billion. Photo: Christopher Occhicone/Bloomberg NewsA true home run in the drug industry is when a company develops a mega-blockbuster that transforms its finances for years. But with Medicare trying to bring costs down by targeting the industry’s most expensive drugs, a portfolio of medium-size moneymakers that can keep your name off the U.S. government’s naughty list can be a wise strategy.

Persons: Christopher Occhicone Organizations: Merck, Bloomberg

☆ This $5 Billion Biotech Home Run Took Less Than a Year
▼ + stars: | 2023-10-24 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Ownership of the drug went from Pfizer to Roivant and then to Roche with stunning speed. Photo: Stefan Wermuth/Bloomberg NewsYou can’t completely blame Pfizer ’s executives, yet Roche ’s $7 billion acquisition of a bowel-disease treatment that it owned until last year isn’t a great look. In a deal that now feels like a biotech version of “Moneyball,” Roivant announced it was selling an asset that only 11 months ago it got for free from Pfizer. Big pharma companies focused on the drug industry equivalent of free agent signings will often overlook one of their own hot prospects. In fact, Republican presidential candidate Vivek Ramaswamy founded Roivant on the idea that pharma’s trash can be another company’s treasure.

Persons: Roche, Stefan Wermuth, Pfizer ’, ” Roivant, Vivek Ramaswamy, Roivant Organizations: Pfizer, Roivant, Bloomberg, Street Journal, Big pharma, Republican

☆ Ozempic Boom Is an Opportunity for Health Insurers
▼ + stars: | 2023-10-20 | by ( David Wainer | ) www.wsj.com time to read: 1 min

WSJ’s Daniela Hernandez breaks down the science of how diabetes drugs work—and how they could change psychiatry. Photo illustration: Elizabeth SmelovYou would think a new class of high-price weight loss drugs taken by millions of Americans would be a problem for health insurers. But it is more complicated than that: Some insurance giants actually stand to profit from the Ozempic craze. The industry has been calling out the costs of GLP-1 drugs, which are used for both diabetes and obesity. But federally supported Medicare and Medicaid still don’t cover the drugs for obesity, and much of the commercial market is self-insured.

Persons: WSJ’s Daniela Hernandez, Elizabeth Smelov, Aetna

☆ Pfizer Looks for a Covid Bottom
▼ + stars: | 2023-10-17 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/health/pharma/pfizer-looks-for-a-covid-bottom-f9b551fa

Persons: Dow Jones Organizations: pharma, pfizer

☆ New Walgreens CEO Needs to Cut the Dividend
▼ + stars: | 2023-10-12 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/business/retail/new-walgreens-ceo-needs-to-cut-the-dividend-d69bb2e4

Persons: Dow Jones Organizations: walgreens

☆ Healthcare Strikes Threaten to Prolong Wage Pressure on Hospitals
▼ + stars: | 2023-10-10 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/health/healthcare/healthcare-strikes-threaten-to-prolong-wage-pressure-on-hospitals-280549fb

Persons: Dow Jones

☆ This Out-of-Favor Sector Is Benefiting From Higher Rates
▼ + stars: | 2023-10-06 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/finance/stocks/this-out-of-favor-sector-is-benefiting-from-higher-rates-f2e854b6

Persons: Dow Jones

☆ Vivek Ramaswamy’s Former Company Is Doing Just Fine Without Him
▼ + stars: | 2023-10-03 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/tech/biotech/vivek-ramaswamys-former-company-is-doing-just-fine-without-him-1a4ecc70

Persons: Dow Jones, 1a4ecc70

☆ Amgen Could Get a Piece of the Obesity Market
▼ + stars: | 2023-09-27 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/finance/stocks/amgen-could-get-a-piece-of-the-obesity-market-5876ba75

Persons: Dow Jones

☆ Blockbuster Cancer Treatment Stymied by Supply Chain—for Now
▼ + stars: | 2023-09-21 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/health/pharma/blockbuster-cancer-treatment-stymied-by-supply-chainfor-now-92723823

Persons: Dow Jones Organizations: pharma

☆ Big Pharma’s Battle With the Biden Administration Could Have Legs
▼ + stars: | 2023-09-09 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/health/pharma/big-pharmas-battle-with-the-biden-administration-could-have-legs-a0524692

Persons: Dow Jones Organizations: biden

☆ Biden FTC’s Antitrust Bark Proves Worse Than Its Bite
▼ + stars: | 2023-09-06 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/finance/investing/biden-ftcs-antitrust-bark-proves-worse-than-its-bite-6ea31209

Persons: Dow Jones, biden

☆ The Ozempic Craze Could Put These Companies on a Crash Diet
▼ + stars: | 2023-08-18 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/health/healthcare/ozempic-mounjaro-wegovy-eli-lilly-novo-nordisk-stock-87d9d1d6

Persons: Dow Jones, eli, lilly Organizations: nordisk

☆ New Treatment for Bladder Cancer Offers This Biotech a Second Chance
▼ + stars: | 2023-08-17 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/health/healthcare/new-treatment-for-bladder-cancer-offers-this-biotech-a-second-chance-b11a9368

Persons: Dow Jones

☆ David Wainer — Columnist at The Wall Street Journal
▼ + stars: | 2023-08-17 | by ( David Wainer | ) www.wsj.com time to read: 1 min

David WainerDavid Wainer is a Heard on the Street columnist based in New York, where he writes about healthcare. David spent over a decade as a correspondent in Israel before moving to New York in 2018. He was awarded the Elizabeth Neuffer gold prize in 2019 for his coverage of China's effort to reshape the United Nations during the Donald Trump presidency. David was born and raised in Rio de Janeiro, Brazil. David has a bachelor's degree in finance from Boston University's Questrom School of Business.

Persons: David Wainer David Wainer, David, Elizabeth Neuffer, Donald Trump Organizations: Bloomberg News, United Nations, Boston University's Questrom School of Business Locations: New York, Israel, Rio de Janeiro, Brazil

☆ Get In on This Skin Disease Drug Before Big Pharma Does
▼ + stars: | 2023-08-15 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/get-in-on-this-skin-disease-drug-before-big-pharma-does-8e4d73c7

Persons: Dow Jones

☆ The Obesity Drug Revolution Just Got Real
▼ + stars: | 2023-08-08 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/the-obesity-drug-revolution-just-got-real-918e958c

Persons: Dow Jones

☆ Those Hip Surgeries Are Now Mostly Priced Into Insurers’ Stocks
▼ + stars: | 2023-08-03 | by ( David Wainer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/those-hip-surgeries-are-now-mostly-priced-into-insurers-stocks-d95e24b8

Persons: Dow Jones

Search resuls for: "David Wainer"

25 mentions found